Free Trial
LON:CEL

Celadon Pharmaceuticals (CEL) Share Price, News & Analysis

Celadon Pharmaceuticals logo
GBX 4.11 -1.89 (-31.50%)
As of 12:38 PM Eastern

About Celadon Pharmaceuticals Stock (LON:CEL)

Key Stats

Today's Range
3.16
6.10
50-Day Range
3
22
52-Week Range
2.21
122.50
Volume
626,330 shs
Average Volume
288,347 shs
Market Capitalization
£2.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Celadon Pharmaceuticals Plc is a UK-based pharmaceutical company focused on the development, production and sale of breakthrough cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism. Its 100,000 sq. ft UK facility is EU-GMP approved and comprises indoor hydroponic cultivation, proprietary GMP extraction and an analytical and R&D laboratory. Celadon's Home Office licence allows for the commercial supply of its pharmaceutical-grade cannabis product. The Group owns an approved clinical trial using cannabis-based medicinal products to treat chronic pain in the UK. Celadon also has a minority interest in early-stage biopharma Kingdom Therapeutics, which is developing a licensed cannabinoid medicine to treat children with Autism Spectrum Disorder. For further information please visit our website www.celadonpharma.com

Remove Ads
Receive CEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celadon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CEL Stock News Headlines

Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Celadon Pharmaceuticals to Delist From AIM
Celadon Pharmaceuticals Share Chat (CEL)
See More Headlines

CEL Stock Analysis - Frequently Asked Questions

Celadon Pharmaceuticals' stock was trading at GBX 14 on January 1st, 2025. Since then, CEL shares have decreased by 70.6% and is now trading at GBX 4.11.
View the best growth stocks for 2025 here
.

Shares of CEL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Celadon Pharmaceuticals investors own include AutoZone (AZO), Bahamas Petroleum (BPC), Intel (INTC), TJX Companies (TJX), Abacus Health Products (ABAHF), Avino Silver & Gold Mines (ASM) and Avino Silver & Gold Mines (ASM).

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
Communication
Current Symbol
LON:CEL
CIK
N/A
Fax
N/A
Employees
2,780
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
£-4,965,636.99
Net Margins
-4,024.62%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£123,381.65
Cash Flow
GBX 1.35 per share
Price / Cash Flow
3.05
Book Value
GBX 3.80 per share
Price / Book
1.08

Miscellaneous

Free Float
N/A
Market Cap
£2.52 million
Optionable
Not Optionable
Beta
-0.26
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (LON:CEL) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners